यह सेवा आपके क्षेत्र में उपलब्ध नहीं है।

6 4 G LTD

यूनाइटेड किंगडम

स्थापित किया गया

२०१५ (11 साल)

स्थापित

आखिरी बार ऑनलाइन: हाल की कोई गतिविधि नहीं

वेबसाइट पर जाएं

TrustScore उपलब्ध नहीं हैरुझान दिखाने के लिए पर्याप्त स्कोर नहीं है।

इस कंपनी को रेट और रिव्यू करने वाले पहले व्यक्ति बनें।

कुल स्कोर

लाइसेंस

--/40

समीक्षाएँ

--/60

0 समीक्षाएँ

TrustFinance द्वारा प्रदान

TrustScore उपलब्ध नहीं हैरुझान दिखाने के लिए पर्याप्त स्कोर नहीं है।

इस कंपनी को रेट और रिव्यू करने वाले पहले व्यक्ति बनें।

FTD LIMITED

(505 समीक्षाएं)

British Virgin Islands

२०१७

(9 वर्ष)

सुरक्षा जानकारी :

BVI FSC

सुरक्षा जानकारी

चेतावनी

यह कंपनी वर्तमान में अप्रमाणित.

कृपया संभावित जोखिमों से सावधान रहें!

लाइसेंस

ए ग्रेड लाइसेंस

विश्व स्तर पर प्रसिद्ध नियामकों द्वारा जारी किए गए, ये लाइसेंस सख्त अनुपालन, फंड सेग्रीगेशन, बीमा और नियमित ऑडिट के माध्यम से उच्चतम व्यापारी सुरक्षा सुनिश्चित करते हैं। विवाद समाधान और AML/CTF मानकों का पालन सुरक्षा को और बढ़ाता है।

बी ग्रेड लाइसेंस

सम्मानित क्षेत्रीय नियामकों द्वारा प्रदान किए गए, ये लाइसेंस फंड सेग्रीगेशन, वित्तीय रिपोर्टिंग और मुआवजा योजनाओं जैसे मजबूत सुरक्षा उपाय प्रदान करते हैं। हालांकि टियर 1 से थोड़ा कम सख्त, वे भरोसेमंद क्षेत्रीय सुरक्षा प्रदान करते हैं।

सी ग्रेड लाइसेंस

उभरते बाजारों में नियामकों द्वारा जारी किए गए, ये लाइसेंस न्यूनतम पूंजी आवश्यकताओं और AML नीतियों जैसे बुनियादी सुरक्षा प्रदान करते हैं। निरीक्षण कम कठोर है, इसलिए व्यापारियों को सावधानी बरतनी चाहिए और सुरक्षा उपायों को सत्यापित करना चाहिए।

डी ग्रेड लाइसेंस

न्यूनतम निरीक्षण वाले न्यायालयों से, इन लाइसेंसों में अक्सर फंड सेग्रीगेशन और बीमा जैसे महत्वपूर्ण सुरक्षा उपायों का अभाव होता है। परिचालन लचीलेपन के लिए आकर्षक होने पर, वे व्यापारियों के लिए उच्च जोखिम पैदा करते हैं।

कंपनी की जानकारी

जानिए 6 4 G LTD

और दिखाएं

कंपनी की जानकारी

जानिए 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

और दिखाएं

उद्योग

विदेशी मुद्रा रिटेल ब्रोकरप्राथमिक
वित्तीय अन्य सेवा

सॉफ्टवेयर

कोई डेटा उपलब्ध नहीं है।

ऐसा लगता है कि यह अनुभाग खाली है। अपडेट्स के लिए जल्द ही वापस आएं!

संपर्क

सोशल

कंपनी ने अपनी जानकारी अपडेट नहीं की है।

समीक्षाएं

6 4 G LTD समीक्षाएं

समीक्षाएं

कुल 0

फ़िल्टर

5 बिन्तांग

4 बिन्तांग

3 बिन्तांग

2 बिन्तांग

1 बिन्तांग

क्रमबद्ध करें

फ़िल्टर

कंपनी की जानकारी

जानिए 6 4 G LTD

और दिखाएं

कंपनी की जानकारी

जानिए 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

और दिखाएं

उद्योग

विदेशी मुद्रा रिटेल ब्रोकरप्राथमिक
वित्तीय अन्य सेवा

सॉफ्टवेयर

कोई डेटा उपलब्ध नहीं है।

ऐसा लगता है कि यह अनुभाग खाली है। अपडेट्स के लिए जल्द ही वापस आएं!

संपर्क

सोशल

कंपनी ने अपनी जानकारी अपडेट नहीं की है।

समाचार

TrustFinance खुफिया एजेंसी

अनुसंधान तिथि: मई १४, २०२६

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

ट्रस्टफाइनेंस एआई विश्लेषण द्वारा प्रदान किया गया

समाचार

TrustFinance खुफिया एजेंसी

अनुसंधान तिथि: मई १४, २०२६

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

ट्रस्टफाइनेंस एआई विश्लेषण द्वारा प्रदान किया गया

6 4 G LTD

FTD LIMITED

कंपनी की जानकारी

कंपनी की जानकारी